Sun Chief Shanghvi Opens Up On Ranbaxy And Future Challenges
This article was originally published in PharmAsia News
Sun Managing Director Dilip Shanghvi was the chief guest at a Hyderabad event last week to launch a book, ‘An Unfinished Agenda’, the memoirs of the late Dr. Anji Reddy, founder of Dr. Reddy’s Laboratories. Shanghvi recalled some of his discussions with Dr. Reddy, and at the sidelines of the event briefed media representatives on the latest developments concerning his company and the overall industry.
You may also be interested in...
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.
India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.